Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 189 participants.
Also called NCT07586865
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 189 participants
- Registry
-
NCT07586865
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07586865. Randomized; quadruple masking; primary purpose treatment. Start 2026-05-18 (anticipated); primary completion 2027-08-17 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction
- Condition
- Acute Myocardial Infarction (AMI)
- Condition
- Acute Myocardial Infarction of Anterior Wall
- Condition
- Acute Myocardial Infarction With ST Elevation
- Condition
- Acute Myocardial Infarction of Left Ventricle
- Condition
- Acute Myocardial Infarction With ST Segment Elevation
- Intervention (Drug)
- Recombinant Human Thymosin Beta 4 Injection (NL005)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Beijing Northland Biotech. Co., Ltd.
Record details
- Record id
cardio:ct-nct07586865- Content hash
b903c2c43f625fe8f4d53158e31fa542c329e9df58f3bd465ba804f8c956c9a5